Zeria Pharmaceutical
CompanyJapan
Zeria Pharmaceutical develops one asset, approved (patiromer in hyperkalemia). Mostly other; based in Japan.
- 1
- Asset
- Furthest stage
- Approved
- 2
- Trials
- 4
- Signals
Pipeline
1Binds potassium in the gastrointestinal tract, increasing fecal potassium excretion and lowering blood potassium.
Approved, Other, hyperkalemia, chronic kidney disease (Phase 2)
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials4
- Signals5
- Similar companies6